I’m excited to be part of an exceptional team leading a business that is so strongly positioned for growth. We are fully focused and ready to deliver 4 to 6% organic annual sales growth over the medium term.”
— Tobias Hestler
Tobias is Haleon’s CFO, having been appointed in December 2021. He had previously held the role of CFO for the Consumer Healthcare division, while the business was still part of GSK. He is also a member of Haleon’s Board of Directors.
Prior to joining GSK in 2017, Tobias was the Chief Financial Officer at Sandoz – Novartis’ Generics Division. In 2010, he was named Chief Financial Officer for the former Novartis Consumer Health Division, a position that evolved into Tobias' role as CFO for the Novartis OTC division. Earlier in his career he held both local and global finance leadership roles at Novartis in the US, Germany and Switzerland, for example as Global Head of Finance for the Animal Health business, Global Controller for Sandoz and CFO for Hexal.
Favourite brand: Voltaren